Israel Englander Millennium Management
Israel “Izzy” Englander is the founder of Millennium Management, one of the world’s largest multi-strategy hedge fund platforms. Millennium allocates capital across hundreds of independent teams rather than a single house view, with rigorous risk controls at the platform level. Englander’s model has been highly influential in the rise of pod-shop multi-manager structures across the industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$643M |
| 2 |
AT&T
T
|
+$311M |
| 3 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$306M |
| 4 |
Microsoft
MSFT
|
+$292M |
| 5 |
Ametek
AME
|
+$215M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$887M |
| 2 |
Apple
AAPL
|
+$694M |
| 3 |
PRAH
PRA Health Sciences, Inc.
PRAH
|
+$616M |
| 4 |
Amazon
AMZN
|
+$596M |
| 5 |
Linde
LIN
|
+$531M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 7.69% |
| 2 | Financials | 6.83% |
| 3 | Healthcare | 6.42% |
| 4 | Industrials | 4.98% |
| 5 | Consumer Discretionary | 4.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
HR
1726
DELISTED
Healthcare Realty Trust Incorporated
HR
| $12.9M | 0.01% |
433,770
-486,614
| -53% | -$14.9M |
|
|
WBA
1727
DELISTED
Walgreens Boots Alliance
WBA
| $12.9M | 0.01% |
274,149
-936,504
| -77% | -$45.2M |
|
|
HCNEU
1728
DELISTED
Jaws Hurricane Acquisition Corp. Unit
HCNEU
| $12.9M | 0.01% |
1,289,791
+8,713
| +0.7% | +$87.2K |
|
1729
Talos Energy
TALO
$2.76B
| $12.9M | 0.01% |
+936,011
| New | +$11.4M |
|
|
CVII
1730
DELISTED
Churchill Capital Corp VII Class A Common Stock
CVII
| $12.9M | 0.01% |
1,325,865
-1,463,204
| -52% | -$14.2M |
|
1731
UiPath
PATH
$8.7B
| $12.9M | 0.01% |
244,716
-8,336
| -3% | -$505K |
|
|
TRCA
1732
DELISTED
Twin Ridge Capital Acquisition Corp.
TRCA
| $12.9M | 0.01% |
1,326,870
+374,293
| +39% | +$3.63M |
|
1733
PUT
MetLife
MET
$61.4B
| $12.9M | 0.01% |
208,300
-315,600
| -60% | -$19M |
|
1734
Sally Beauty Holdings
SBH
$1.56B
| $12.9M | 0.01% |
763,107
+573,719
| +303% | +$10.9M |
|
1735
C4 Therapeutics
CCCC
$503M
| $12.8M | 0.01% |
287,573
-96,975
| -25% | -$4.15M |
|
|
AHPAU
1736
DELISTED
Avista Public Acquisition Corp. II Unit
AHPAU
| $12.8M | 0.01% |
+1,269,543
| New | +$12.8M |
|
|
EWCZ
1737
DELISTED
European Wax Center
EWCZ
| $12.8M | 0.01% |
+458,246
| New | +$11.5M |
|
1738
OSI Systems
OSIS
$3.34B
| $12.8M | 0.01% |
135,386
+48,730
| +56% | +$4.75M |
|
1739
CALL
Neurocrine Biosciences
NBIX
$15.7B
| $12.8M | 0.01% |
133,700
-16,300
| -11% | -$1.54M |
|
|
COR
1740
DELISTED
Coresite Realty Corporation
COR
| $12.8M | 0.01% |
+92,432
| New | +$13.2M |
|
1741
PUT
iPath Series B S&P 500 VIX Short-Term Futures ETN
VXX
$135M
| $12.8M | 0.01% |
28,750
-11,836
| -29% | -$5.31M |
|
|
PACX
1742
DELISTED
Pioneer Merger Corp. Class A Ordinary Share
PACX
| $12.8M | 0.01% |
1,288,985
+201,697
| +19% | +$2M |
|
1743
PUT
NIO
NIO
$11.1B
| $12.8M | 0.01% |
358,800
+280,000
| +355% | +$11.5M |
|
1744
Aemetis
AMTX
$134M
| $12.8M | 0.01% |
698,839
+278,356
| +66% | +$3.08M |
|
|
HERAU
1745
DELISTED
FTAC Hera Acquisition Corp. Units
HERAU
| $12.8M | 0.01% |
1,281,004
-596,848
| -32% | -$5.97M |
|
1746
PUT
Qorvo
QRVO
$8.29B
| $12.7M | 0.01% |
76,100
+70,900
| +1,363% | +$13.2M |
|
|
CHAA
1747
DELISTED
Catcha Investment Corp
CHAA
| $12.7M | 0.01% |
1,299,587
+687,550
| +112% | +$6.66M |
|
1748
Leidos
LDOS
$17.1B
| $12.7M | 0.01% |
131,796
-47,056
| -26% | -$4.67M |
|
1749
CALL
Labcorp
LH
$27.2B
| $12.7M | 0.01% |
52,380
+29,100
| +125% | +$7.33M |
|
1750
NCR Voyix
VYX
$1.14B
| $12.7M | 0.01% |
532,365
+248,104
| +87% | +$6.46M |
|
Similar funds
Israel Englander's Q3 2021 Portfolio in Review
As of Q3 2021, Israel Englander held 7,698 positions worth $167B, up 2.3% from $163B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Israel Englander deployed $8.65B of net new capital in Q3 2021, opening 1,245 new positions and adding to 2,719 existing holdings. Its largest new stake was Sight Sciences: 1,577,092 shares worth $35.8M.
By sector, the portfolio is most concentrated in Technology at 7.7% of assets, down from 8.2% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Apple, an estimated $694M trimmed.
- Israel Englander's largest Q3 2021 buy was Sight Sciences: 1,577,092 shares worth $35.8M.
- Israel Englander added most to State Street SPDR S&P 500 ETF Trust in Q3 2021, an estimated $643M increase.
- Israel Englander's biggest Q3 2021 reduction was Apple, cutting an estimated $694M.
- Israel Englander fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $887M.
- Israel Englander's ten largest holdings make up 18% of its $167B portfolio in Q3 2021.
- Israel Englander opened 1,245 new positions and closed 981 in Q3 2021.
- Israel Englander's portfolio value rose 2.3% quarter-over-quarter to $167B.
Based on Millennium Management's 13F filing for Q3 2021, filed 15 Nov 2021.